{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:43Z","timestamp":1790166223799,"version":"4.1.0"},"reference-count":33,"publisher":"Portland Press Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":443,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,29]]},"abstract":"<jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative disease which uniquely expresses a constitutively active tyrosine kinase, BCR\/ABL. As a specific inhibitor of the BCR-ABL tyrosine kinase, imatinib becomes the first choice for the treatment of CML due to its high efficacy and low toxicity. However, the development of imatinib resistance limits the long-term treatment benefits of it in CML patients. In the present study, we aimed to investigate the roles of miR-202 in the regulation of imatinib sensitivity in CML cell lines and the possible mechanisms involved in this process. We found miR-202 was down-regulated in seven CML cell lines by quantitative reverse-transcription PCR (qRT-PCR) analysis. Overexpression of miR-202 significantly suppressed proliferation rates of CML cells. By establishing imatinib resistant cell lines originating from K562 and KU812 cells, we observed expressions of miR-202 were down-regulated by imatinib treatments and imatinib resistant CML cell lines exhibited lower level of miR-202. On the contrary, imatinib resistant CML cell lines displayed up-regulated glycolysis rate than sensitive cells with the evidence that glucose uptake, lactate production, and key glycolysis enzymes were elevated in imatinib resistant cells. Importantly, the imatinib resistant CML cell lines were more sensitive to glucose starvation and glycolysis inhibitors. In addition, we identified Hexokinase 2 (HK2) as a direct target of miR-202 in CML cell lines. Overexpression of miR-202 sensitized imatinib resistant CML through the miR-202-mediated glycolysis inhibition by targetting HK2. Finally, we provided the clinical relevance that miR-202 was down-regulated in CML patients and patients with lower miR-202 expression displayed higher HK2 expression. The present study will provide new aspects on the miRNA-modulated tyrosine kinase inhibitor (TKI) sensitivity in CML, contributing to the development of new therapeutic anticancer drugs.<\/jats:p>","DOI":"10.1042\/bsr20171383","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T18:00:45Z","timestamp":1521568845000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Overexpression of <i>miR-202<\/i> resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2"],"prefix":"10.1042","volume":"38","author":[{"given":"Yingjun","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Abdominal Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China 510095"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong,China 510095"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Abdominal Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China 510095"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Abdominal Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China 510095"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"2021111618560657600_B1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and treatment of chronic myeloid leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"Suppl 2","key":"2021111618560657600_B2","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European Leukemianet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann. Hematol."},{"key":"2021111618560657600_B3","first-page":"357027","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"2021111618560657600_B4","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.1038\/sj.onc.1206082","article-title":"BCR\/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia","volume":"21","author":"Salesse","year":"2002","journal-title":"Oncogene"},{"key":"2021111618560657600_B5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.clml.2013.05.012","article-title":"A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2021111618560657600_B6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European Leukemianet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"2021111618560657600_B7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jnci\/djr073","article-title":"Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects","volume":"103","author":"Smith","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"2021111618560657600_B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"2021111618560657600_B9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"2021111618560657600_B10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"2021111618560657600_B11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-94-007-6621-1_18","article-title":"Regulation of stem cell populations by microRNAs","volume":"786","author":"Mathieu","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"2021111618560657600_B12","doi-asserted-by":"publisher","first-page":"a008144","DOI":"10.1101\/cshperspect.a008144","article-title":"microRNAs as developmental regulators","volume":"7","author":"Ivey","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2021111618560657600_B13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cmet.2013.06.004","article-title":"MicroRNAs and metabolism crosstalk in energy homeostasis","volume":"18","author":"Dumortier","year":"2013","journal-title":"Cell Metab."},{"key":"2021111618560657600_B14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in cancer: biomarkers, functions and therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol. Med."},{"key":"2021111618560657600_B15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"2021111618560657600_B16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review","volume":"4","author":"Iorio","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"2021111618560657600_B17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2013.04.002","article-title":"MicroRNAs in hematological malignancies","volume":"27","author":"Lawrie","year":"2013","journal-title":"Blood Rev."},{"key":"2021111618560657600_B18","doi-asserted-by":"publisher","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","article-title":"Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells","volume":"7","author":"Rokah","year":"2012","journal-title":"PLoS ONE"},{"key":"2021111618560657600_B19","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1038\/oncsis.2017.58","article-title":"miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and \u03b11,3-fucosylated glycans","volume":"6","author":"Zheng","year":"2017","journal-title":"Oncogenesis"},{"key":"2021111618560657600_B20","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.febslet.2014.03.030","article-title":"miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally","volume":"588","author":"Zhang","year":"2014","journal-title":"FEBS Lett."},{"key":"2021111618560657600_B21","doi-asserted-by":"publisher","first-page":"e69756","DOI":"10.1371\/journal.pone.0069756","article-title":"Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer","volume":"8","author":"Zhao","year":"2013","journal-title":"PLoS ONE"},{"key":"2021111618560657600_B22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4161\/15384047.2014.987070","article-title":"Down regulation of miR-202 modulates Mxd1 and Sin3A repressor complexes to induce apoptosis of pancreatic cancer cells","volume":"16","author":"Farhana","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"2021111618560657600_B23","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.3892\/mmr.2017.6841","article-title":"miR-202 functions as a tumor suppressor in non-small cell lung cancer by targeting STAT3","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"2021111618560657600_B24","doi-asserted-by":"publisher","first-page":"72067","DOI":"10.18632\/oncotarget.12499","article-title":"miR-202 inhibits the progression of human cervical cancer through inhibition of cyclin D1","volume":"7","author":"Yi","year":"2016","journal-title":"Oncotarget"},{"key":"2021111618560657600_B25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021111618560657600_B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12957-016-0769-9","article-title":"Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer","volume":"14","author":"Li","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"2021111618560657600_B27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2014.09.003","article-title":"2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy","volume":"355","author":"Zhang","year":"2014","journal-title":"Cancer Lett."},{"key":"2021111618560657600_B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2014.11.046","article-title":"Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: involvement of the Akt-mTOR signaling pathway","volume":"358","author":"Zhao","year":"2015","journal-title":"Cancer Lett."},{"key":"2021111618560657600_B29","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1111\/j.1582-4934.2011.01274.x","article-title":"Epigenetic inactivation of the hsa-miR-203 in haematological malignancies","volume":"15","author":"Chim","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"2021111618560657600_B30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"2021111618560657600_B31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1476-4598-12-152","article-title":"Tumor glycolysis as a target for cancer therapy: progress and prospects","volume":"12","author":"Ganapathy-Kanniappan","year":"2013","journal-title":"Mol. Cancer"},{"key":"2021111618560657600_B32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4068\/cmj.2014.50.3.102","article-title":"OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib","volume":"50","author":"Kim","year":"2014","journal-title":"Chonnam. Med. J."},{"key":"2021111618560657600_B33","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","article-title":"Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells","volume":"15","author":"Kominsky","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20171383\/808080\/bsr-2017-1383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20171383\/808080\/bsr-2017-1383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T19:36:16Z","timestamp":1637091376000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/38\/3\/BSR20171383\/57592\/Overexpression-of-miR-202-resensitizes-imatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6,29]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20171383","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"article-number":"BSR20171383"}}